Drugs that target the GLP-1 receptor (GLP-1R) range from single agonists like semaglutide to dual agents like tirzepatide and triple agonists like retatrutide. They all bind and activate the same receptor, but the newer ones hit additional receptors at the same time. How many receptors a molecule engages, and how long it stays bound, largely explains how they differ in the clinic.
What does it mean to target the GLP-1 receptor?
The GLP-1 receptor is a G-protein-coupled receptor found on pancreatic beta cells, in the gut, the heart, and critically in appetite centers of the brain such as the hypothalamus and brainstem. When the natural hormone GLP-1 binds it, the receptor triggers glucose-dependent insulin release, slows gastric emptying, and signals fullness. A drug that "targets" GLP-1R is one engineered to bind and switch on that same receptor.
The catch with the natural hormone is speed: GLP-1 is degraded by the enzyme DPP-4 within about two minutes. Every drug in this class is built to dodge that problem, so the receptor stays activated for hours or days rather than seconds. For the plain-language version of the term, see what GLP-1 receptor agonist actually means.
How do you turn the GLP-1 receptor into a drug?
There are two structural strategies, and a couple of design tricks shared across the class.
Peptide versus small molecule
Most GLP-1R drugs are peptides, modified versions of the hormone's amino-acid sequence that resist DPP-4 and often bind to albumin in the blood to extend their half-life. That is how once-weekly dosing became possible. A newer approach uses non-peptide small molecules, such as orforglipron, that can be swallowed as a conventional pill without the strict fasting requirements of peptide tablets.
Half-life and dosing
The original agents were short-acting and dosed daily or twice daily, concentrating their effect around meals. Engineering longer half-lives produced continuous receptor activation, which turns out to matter for appetite: sustained signaling reaches the brain's intake centers far more effectively than pulsed mealtime exposure, which is part of why long-acting agents drive more weight loss.
Which drugs are single-target GLP-1 receptor agonists?
These activate GLP-1R alone. They were the first generation and remain the most widely used.
- Exenatide (Byetta, Bydureon), derived from a Gila monster peptide, the first approved in 2005.
- Lixisenatide (Adlyxin), a short-acting daily agent.
- Liraglutide (Victoza, Saxenda), once daily.
- Dulaglutide (Trulicity), once weekly.
- Semaglutide (Ozempic, Wegovy, Rybelsus), once weekly or as a daily tablet.
- Orforglipron, an investigational oral small-molecule agonist.
For how these single agonists stack up against each other, the full GLP-1 receptor agonist class guide goes drug by drug, and the drugs similar to semaglutide overview maps the closest alternatives.
Which drugs hit GLP-1 plus a second receptor?
Combining GLP-1R with another incretin or metabolic receptor is the defining move of the second generation.
GIP plus GLP-1
Tirzepatide (Mounjaro, Zepbound) activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Adding GIP agonism boosted both A1C and weight loss beyond single-receptor agents in the SURPASS and SURMOUNT programs. The mechanics are covered in what tirzepatide is and how the dual agonist works.
GLP-1 plus glucagon
Another branch pairs GLP-1R with the glucagon receptor. Glucagon agonism can raise energy expenditure and act on liver fat, while GLP-1 keeps glucose and appetite in check. Survodutide, mazdutide, and cotadutide are investigational examples in this group.
Which drugs target three receptors at once?
The newest tier is the triple agonist. Retatrutide activates the GLP-1, GIP, and glucagon receptors simultaneously, aiming to combine the appetite and glucose effects of the incretins with the energy-expenditure effect of glucagon. It remains investigational, and the retatrutide mechanism of action and what retatrutide is explainers cover how the triple-target approach is meant to work.
How the receptor targets line up
| Drug | GLP-1R | GIP-R | Glucagon-R | Status |
|---|---|---|---|---|
| Exenatide | Yes | No | No | Approved |
| Liraglutide | Yes | No | No | Approved |
| Dulaglutide | Yes | No | No | Approved |
| Semaglutide | Yes | No | No | Approved |
| Orforglipron | Yes | No | No | Investigational |
| Tirzepatide | Yes | Yes | No | Approved |
| Survodutide | Yes | No | Yes | Investigational |
| Mazdutide | Yes | No | Yes | Investigational |
| Retatrutide | Yes | Yes | Yes | Investigational |
Why does receptor selectivity change the results?
Each receptor contributes a different effect, so the combination a molecule targets shapes its clinical profile. GLP-1R drives appetite suppression and glucose-dependent insulin release. GIP-R adds further insulin and appetite effects and may temper nausea. Glucagon-R agonism, counterintuitively paired with insulin-promoting partners, can increase energy expenditure and reduce liver fat without raising blood sugar because the GLP-1 component offsets glucagon's glucose-raising tendency. Adding receptors has generally increased weight-loss magnitude in trials, but it also adds complexity to dosing and side-effect profiles, which is why the multi-agonists are titrated carefully.
How did the GLP-1 receptor become a drug target?
The story starts with the incretin effect: researchers noticed that glucose taken by mouth triggers far more insulin than the same glucose given intravenously, because gut hormones, the incretins GLP-1 and GIP, amplify the response. GLP-1 looked like an ideal diabetes drug except that it vanished within minutes. The breakthrough came from an unlikely source: exendin-4, a peptide in the venom of the Gila monster that activates the human GLP-1 receptor but resists rapid breakdown. Synthesized as exenatide, it became the first GLP-1 receptor agonist in 2005. Every later drug refined the same idea, extending half-life and, eventually, adding more receptors, turning a two-minute hormone into the foundation of an entire drug class.
Frequently Asked Questions
Is tirzepatide a GLP-1 drug?
It targets the GLP-1 receptor but also the GIP receptor, making it a dual agonist rather than a single GLP-1 agent. It is often grouped with GLP-1 drugs because GLP-1R activation is central to how it works.
What is the difference between a single, dual, and triple agonist?
A single agonist activates only GLP-1R. A dual agonist adds one more receptor, either GIP or glucagon. A triple agonist hits GLP-1, GIP, and glucagon receptors together. More receptors have generally meant greater weight loss in trials.
Are any oral drugs targeting the GLP-1 receptor?
Yes. Rybelsus is an oral peptide tablet of semaglutide taken on an empty stomach, and orforglipron is an investigational small-molecule pill that does not require fasting.
Why target glucagon if it raises blood sugar?
Glucagon agonism increases energy expenditure and helps clear liver fat. In combination drugs, the GLP-1 component keeps glucose controlled, so the net effect on blood sugar stays favorable.
This article is for general education and is not medical advice. Several drugs described here are investigational and not FDA-approved. Consult a licensed clinician about any medication.